JX09 vs VB19055
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline
JX09
Developed by Ji Xing Pharmaceuticals (CORXEL)
NCT06183671 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled phase 1 study in 92 healthy volunteers testing single and multiple ascending doses of JX09, with safety and tolerability as the primary focus rather than a disease efficacy measure. Results have not been posted.
No aligned efficacy figure on record for this race.
VB19055
Developed by Yangli Pharmaceutical Technology
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07833098 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | JX09 | VB19055 |
|---|---|---|
| Seated SBP, change | —Not reported | —Not reported |
| 24-hour ambulatory SBP, change | —Not reported | —Not reported |
| Seated DBP, change | —Not reported | —Not reported |
Seated SBP, change
- JX09
- —Not reported
- VB19055
- —Not reported
24-hour ambulatory SBP, change
- JX09
- —Not reported
- VB19055
- —Not reported
Seated DBP, change
- JX09
- —Not reported
- VB19055
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JX09: no structured comparison results are available for Hypertension.
VB19055: no structured comparison results are available for Hypertension.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JX09's landscape · VB19055's landscape